轩竹生物-B(02575)首挂上市，公告显示，每股定价11.60港元，共发行6733.35万股股份，每手500股， 所得款项净额约7.01亿港元。截至发稿，涨153.97%，报29.46港元，成交额2.57亿港元。 公开资料显示，轩竹生物是一家以创新为驱动的中国生物制药公司。自四环医药控股集团有限公司于 2008年收购山东轩竹医药科技有限公司多数权益以来，轩竹已经建立一个全面的内部研发平台，支持公 司开发多样化且均衡的管线。截至最后实际可行日期，公司有超过十种药物资产在积极开发中，涵盖消 化系统疾病、肿瘤和非酒精性脂肪性肝炎(NASH)，包括三项NDA批准资产，一个药物项目处于NDA注 册阶段，一个药物项目处于III期临床试验阶段，四个药物项目处于I期临床试验阶段，五个已获IND批 准。 在公司的管线中，公司有三款核心产品，即KBP-3571(已获NDA批准的治疗消化系统疾病的创新质子泵 抑制剂(PPI))、XZP-3287(已获NDA批准的靶向乳腺癌的细胞週期蛋白依赖性激酶4/6(CDK4/6)抑制剂)和 XZP-3621(已获NDA批准的靶向非小细胞肺癌(NSCLC)的间变性淋巴瘤激酶(ALK)抑制剂)。 ...

在公司的管线中，公司有三款核心产品，即KBP-3571(已获NDA批准的治疗消化系统疾病的创新质子泵 抑制剂(PPI))、 XZP-3287(已获NDA批准的靶向乳腺癌的细胞週期蛋白依赖性激酶4/6 (CDK4/6)抑制剂) 和XZP-3621(已获NDA批准的靶向非小细胞肺癌(NSCLC)的间变性淋巴瘤激酶(ALK)抑制剂)。这种管线 设计从战略上平衡了开发风险和创新，使公司的商业化或后期资产能够支持公司早期创新药物的开发。 智通财经APP获悉，轩竹生物-B(02575)首挂上市，公告显示，每股定价11.60港元，共发行6733.35万股 股份，每手500股，所得款项净额约7.01亿港元。截至发稿，涨153.97%，报29.46港元，成交额2.57亿港 元。 公开资料显示，轩竹生物是一家以创新为驱动的中国生物制药公司。自四环医药控股集团有限公司于 2008年收购山东轩竹医药科技有限公司多数权益以来，轩竹已经建立一个全面的内部研发平台，支持公 司开发多样化且均衡的管线。截至最后实际可行日期，公司有超过十种药物资产在积极开发中，涵盖消 化系统疾病、肿瘤和非酒精性脂肪性肝炎(NASH)，包括三项NDA批准资产，一 ...

Core Viewpoint - Xuan Zhu Bio-B (2575.HK), spun off from Sihuan Pharmaceutical, saw a significant first-day listing increase of 153.97%, opening at HKD 29.46, compared to its IPO pricing of HKD 11.6 [1] Company Overview - Xuan Zhu Bio is an innovation-driven biopharmaceutical company in China, focusing on improving patient health and life through a deep understanding of the Chinese pharmaceutical industry and its unique clinical needs [1] - Since Sihuan Pharmaceutical acquired a majority stake in Shandong Xuan Zhu in 2008, the company has established a comprehensive internal R&D platform to support a diverse and balanced pipeline [1] Product Pipeline - As of the last feasible date, Xuan Zhu Bio has over ten drug assets actively in development, targeting diseases such as digestive system disorders, tumors, and non-alcoholic steatohepatitis (NASH) [1] - The pipeline includes three assets with NDA approval, one project in the NDA registration stage, one project in Phase III clinical trials, four projects in Phase I clinical trials, and five projects that have received IND approval [1] IPO Performance - The public offering was oversubscribed by 4,908.33 times, while the international placement was oversubscribed by 10.15 times [1] - The stock's opening price of HKD 29.46 represents a significant increase from the IPO price, indicating strong market interest and investor confidence [2]

Core Insights - XuanZhu Bio-B (2575.HK) officially listed on the Hong Kong Stock Exchange on October 15, 2023, showing strong market performance and becoming a significant player in the Hong Kong innovative drug sector [1] - The company achieved a subscription rate of 4,908.33 times for its public offering and 10.15 times for international offerings, indicating robust market expectations [1] - The listing is seen as a key positive signal for the recovery of China's innovative drug industry, marking a transition from an adjustment phase to a growth phase [1] Company Overview - XuanZhu Bio has transformed from a purely research-driven biotech company to a comprehensive biopharma entity, achieving approval for three innovative drugs within three years [1][3] - The company has successfully addressed clinical pain points for Chinese patients through differentiated innovation, enhancing its drug development efficiency [3] Product Pipeline - **Digestive Field**: Annelazole Sodium is the first domestically developed proton pump inhibitor (PPI) that reduces drug interaction risks and is suitable for long-term use in elderly patients. It has shown efficacy in clinical trials, with 81.2% of patients experiencing symptom relief on the first day of treatment [4] - **Oncology Field**: - **Pyrrolisib**: A new treatment option for HR+/HER2- advanced breast cancer, expected to launch in July 2025, addressing a significant treatment gap in this patient population [5] - **Girocib**: A next-generation ALK inhibitor for ALK-positive non-small cell lung cancer, with a 57.8% reduction in disease progression or death risk, anticipated to receive approval in August 2025 [6] Strategic Framework - The company employs a three-pronged strategy of pipeline, platform, and commercialization to build a competitive moat in the biopharma sector [7][8] - The pipeline is structured to balance risk and growth, focusing on mature markets while exploring emerging opportunities in areas like NASH (non-alcoholic steatohepatitis) [9][10] Technological Advancements - XuanZhu Bio has established three core technology platforms that enhance research and development efficiency, including small molecule drug development, biopharmaceutical engineering, and clinical development [13] - The small molecule platform utilizes advanced design techniques to create highly selective and safe drug candidates [13] Commercialization Strategy - The company has built an integrated "product-channel-payment" model to realize the value of its innovative drugs, with Annelazole Sodium achieving sales of 48 million yuan since its commercialization in November 2023 [14] - A nationwide distribution network has been established, with over 90 distributors and access to more than 1,500 hospitals, facilitating the commercialization of new products [15] Future Outlook - The listing marks a milestone in XuanZhu Bio's transition from biotech to biopharma, with a focus on leveraging its platform advantages for long-term value creation [16][18] - The company is positioned to become a core representative in the biopharma sector, contributing significantly to the development of China's innovative drug industry [18]

Core Points - Xuan Zhu Bio-B (02575) announced the results of its share allocation, with a total of 67.335 million H-shares globally offered [1] - The offering consisted of 10% for public sale in Hong Kong and 90% for international sale [1] - The final offer price was set at HKD 11.6 per share, raising approximately HKD 701 million in net proceeds from the global offering [1] - Each board lot consists of 500 shares, and trading of the H-shares is expected to commence on October 15, 2025, at 9:00 AM Hong Kong time [1] - The Hong Kong public offering was oversubscribed by 4,908.33 times, while the international offering was oversubscribed by 10.15 times [1]

Core Viewpoint - The company Xuan Zhu Bio-B (02575.HK) has announced a global offering of 67,333,500 H-shares at a price of HKD 11.60 per share, raising a net amount of HKD 701 million [1] Summary by Categories Offering Details - The global offering consists of 67,333,500 H-shares priced at HKD 11.60 each [1] - The net proceeds from the offering amount to HKD 701 million [1] Subscription Demand - The number of shares available for public offering in Hong Kong accounts for 10.00% of the total offering, with a subscription rate of 4,908.33 times [1] - The international offering represents 90.00% of the total shares, with a subscription rate of 10.15 times [1] Trading Information - If the global offering becomes unconditional by October 15, 2025, the H-shares are expected to start trading on the Hong Kong Stock Exchange at 9:00 AM (Hong Kong time) on the same day [1] - H-shares will be traded in lots of 500 shares, with the stock code 2575 [1]

Core Viewpoint - Xuan Zhu Bio-B (02575) has successfully completed its global offering, raising approximately HKD 701 million through the issuance of H-shares at a price of HKD 11.6 per share [1] Summary by Category Offering Details - The company issued a total of 67.33 million H-shares, with 10% allocated for public offering in Hong Kong and 90% for international offering [1] - Each board lot consists of 500 shares, and trading is expected to commence on October 15, 2025, at 9:00 AM Hong Kong time [1] Subscription Demand - The Hong Kong public offering was oversubscribed by 4,908.33 times, indicating strong local investor interest [1] - The international offering saw a subscription rate of 10.15 times, reflecting robust demand from global investors [1]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 除本公告另有界定外，本公告所用詞彙與軒竹生物科技股份有限公司（「本公司」）日期為2025年 10月6日的招股章程（「招股章程」）所界定者具有相同涵義。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。本公告並非招股章程。 潛在投資者在決定是否投資於發售股份前，應細閱招股章程內有關下文所述全球發售的詳細資 料。有關發售股份的任何投資決定應僅依賴招股章程所提供的資料而作出。 本公告不會直接或間接於或向美國（包括美國的領土及屬地、美國任何州以及哥倫比亞特區）發 佈、刊發或派發。本公告並不構成亦不屬於在美國境內或於任何其他司法權區購買或認購證券 的任何要約或招攬的一部分。本公告所述證券並無亦不會根據1933年美國證券法（經不時修訂） （「美國證券法」）或美國任何州或其他司法權區的證券法登記。證券不得在美國境內提呈發售、 出售、質押或以其他方式轉讓 ...

Core Viewpoint - Xuan Zhu Bio-B (02575) is set to list in Hong Kong on October 15, with significant pre-listing trading activity indicating strong investor interest, as evidenced by a 171.21% increase in its dark market price compared to the offering price [1] Group 1 - Xuan Zhu Bio-B's dark market trading price reached HKD 31.46, up from the offering price of HKD 11.60 [1] - The increase in price translates to a profit of HKD 9,930 per lot of 500 shares, excluding transaction fees [1]

26.20万 31.460 250( 150( 31.440 200( 31.420 31.400 MACD MACD(12,26,9):0.090 DIF:0.334 DEA:0.289 31.380 31.360 31.340 31.320 16:15 18:30 分时 1分 5分 日K 立即买入 立即卖出 • 行情来源: 利弗莫尔证券 • | V | | | 31.880 31.860 | | | --- | --- | --- | --- | --- | | | | | 31.840 31.820 31.800 | | | 11.600 | | | 31.780 | 200( | | | | | 31.760 | | | | | | 31.740 | | | | 일본의 일본 | | 31.720 | | | | | | 31.700 | 3000 | | | | | 31.500 | 200( | | -9.267 ● 价位 ● 均价 | | -179.89% | 31.480 | | | 分时量 量:0 | = | | | | 轩竹生物-B(02575)将于10月15日(周三)在香港挂牌。截至收盘 ...